Merck Drives Into Immunotherapy “Wild West” With New Trials

Company moves fast to test pembrolizumab in head and neck cancer, among other new frontier tumor types. The firm has reorganized its oncology business to prepare for launch in melanoma, which will be a critical test of the company’s ambitions to become a cancer powerhouse.